Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
J Clin Oncol. 28: 1904-1910. 2010. 4.
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Jpn J Clin Oncol. 40: 913-920. 2010. 5.
An embryo-specific expressing TGF-β family protein, growth-differentiation factor 3 (GDF3), augments progression of B16 melanoma.
J Exp Clin Cancer Res. 29: 135. 2010. 10.
ZAPS is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.
Nat Immunol. 12: 37-44. 2011. 1.
Sensitive assay for the quantification of hepatitis B virus mutants by a minor groove binder probe and peptide nucleic acids.
J Clin Microbiol. 48: 4487-4494. 2010. 12.
The feasibility for Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma.
Exp Mol Pathol. 90: 55-60. 2011. 2.
Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan.
Blood. 116: 1211-1219. 2010. 8.
Pathophysiological classification of functional dyspepsia using a novel drinking-ultrasonography test.
Digestion. 82: 162-166. 2010. 6.
Lafutidine prevents low-dose aspirin and loxoprofen induced gastric injury: A randomized, double-blinded, placebo controlled study.
J Gastroenterol Hepatol. 25: 1631-1635. 2010. 10.
IgG4-related sclerosing cholangitis and autoimmune pancreatitis: Histological assessment of biopsies from Vater's ampulla and the bile duct.
J Gastroenterol Hepatol. 25: 1648-1655. 2010. 10.
Endoscopic nasobiliary drainage is most suitable for preoperative management in patients with hilar cholangiocarcinoma.
J Gastroenterol. 46: 242-248. 2011. 2.
Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia.
Int J Hematol. 92: 481-489. 2010. 10.
Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.
Aliment Pharmacol Ther. 33: 213-214. 2011. 1.
p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5.
Int J Cancer. 128: 304-318. 2011. 1.
Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Adv Ther. 27: 483-492. 2010. 6.
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Clin Cancer Res. 16: 3964-3975. 2010. 8.
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Lancet Oncol. 11: 853-860. 2010. 8.
Investigation of gastroduodenal mucosal injuries caused by low-dose aspirin therapy in patients with cerebral infarction.
J Gastroenterol Hepatol. 25: S119-S121. 2010. 5.
Comparative study of therapeutic effects of PPI and H2RA on ulcers during continuous aspirin therapy.
World J Gastroenterol. 42: 5342-5346. 2010. 11.
Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
Blood. 116: 4368-4375. 2010. 11.
Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission.
Blood. 117: 3698-3699. 2011. 3.
DNA vaccination targeting macrophage migration inhibitory factor prevents murine experimental colitis.
Clin Exp Immunol. 163: 113-122. 2011. 1.
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Cancer Sci. 102: 425-431. 2011. 2.
Long-term treatment of localized gastric marginal zone B-cell mucosa associated lymphoid tissue lymphoma including incidence of metachronous gastric cancer.
J Gastroenterol Hepatol. 25: 804-809. 2010. 4.
Evaluation of therapeutic effects and serious complications following endoscopic obliterative therapy with Histoacryl.
Clin Exp Gastroenterol. 3: 91-95. 2010. 7.
Retrospective analysis of endoscopic injection sclerotherapy for rectal varices compared with band ligation.
Clin Exp Gastroenterol. 3: 159-163. 2010. 12.
Increased risk of bacterial infection after engraftment in patients treated with allogeneic bone marrow transplantation following reduced-intensity conditioning regimen.
Transpl Infect Dis. 12: 412-420. 2010. 10.
Signaling from fibroblast growth factor receptor 2 in immature hematopoietic cells facilitates donor hematopoiesis after intra-bone marrow-bone marrow transplantation.
Stem Cells Dev. 19: 1679-1689. 2010. 11.
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS.
Jpn J Clin Oncol. 40: 699-701. 2010. 4.
Reduced intensity conditioning regimen with fludarabine, busulfan, and low-dose TBI (Flu-BU2-TBI): clinical efficacy in high-risk patients.
Am J Hematol. 85: 243-248. 2010. 4.
Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization.
Int J Oncol. 36: 1379-1386. 2010. 6.
Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas.
Leuk Lymphoma. 50: 813-821. 2010. 5.